Arthur F. Ryan - 02 Jul 2026 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Reporting relationship: Director
Issuer ticker: REGN
Reported as of: 02 Jul 2026
Net transaction value: -$130,030
SEC form: 4
Accepted by SEC: 07 Jul 2026, 16:05:04 UTC
Prior SEC filing: 04 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Arthur F. Ryan

Key filing fact

Arthur F. Ryan filed Form 4 for REGENERON PHARMACEUTICALS, INC. (REGN) on 07 Jul 2026.

Key facts

This page summarizes Arthur F. Ryan's Form 4 filing for REGENERON PHARMACEUTICALS, INC. (REGN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Jul 2026, 16:05.

Change

Previous filing in this sequence was filed on 04 May 2026.
Current net transaction value: -$130,030.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001187443 Primary reporting owner

RYAN ARTHUR F

Relationship: Director
Address: 777 OLD SAW MILL RIVER ROAD, TARRYTOWN
Signature: /s/ Arthur F. Ryan
Signature date: 07 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

REGN transaction

Common Stock

Sale

Transaction value: $130,030
Shares: -200
Change %: -1.1%
Price: $650.15
Shares after: 17,303
Date: 02 Jul 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.

Footnote F2

Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price.